{"id":46444,"date":"2022-07-21T17:02:20","date_gmt":"2022-07-21T15:02:20","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/innovaderm-shines-as-key-partner-in-clinical-development-and-study-management-of-newly-fda-approved-psoriasis-drug-tapinarof\/"},"modified":"2022-07-21T17:02:20","modified_gmt":"2022-07-21T15:02:20","slug":"innovaderm-shines-as-key-partner-in-clinical-development-and-study-management-of-newly-fda-approved-psoriasis-drug-tapinarof","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/innovaderm-shines-as-key-partner-in-clinical-development-and-study-management-of-newly-fda-approved-psoriasis-drug-tapinarof\/","title":{"rendered":"Innovaderm Shines as Key Partner in Clinical Development and Study Management of Newly FDA-Approved Psoriasis Drug, Tapinarof"},"content":{"rendered":"
\n

MONTREAL–(BUSINESS WIRE)–#DermatologyCRO<\/a>–Innovaderm\u2019s involvement in all phases of the clinical development of tapinarof culminated with a tremendous achievement: the recent approval of Dermavant Sciences\u2019 VTAMA\u00ae (tapinarof) cream by the FDA for the treatment of plaque psoriasis in adults.\n<\/p>\n

<\/a><\/p>\n

\nDiscovered in Canada, tapinarof is approved in the United States for the management of psoriasis, a chronic skin condition that causes itchy, scaly patches on different parts of the body and has a significant detrimental effect on quality of life.\n<\/p>\n

\n\u201cThis is a great milestone for patients \u2013 one that we have been working towards for years,\u201d says Dr. Robert Bissonnette, Innovaderm\u2019s founder and CEO. \u201cInnovaderm is well-positioned to help companies such as Dermavant drive innovation forward by accompanying them in all stages of their clinical research from protocol writing to data analysis. We not only played an instrumental role through our participation in multicenter phase 2 and 3 studies, but we were also the first to demonstrate tapinarof\u2019s efficacy in proof-of-concept studies in both psoriasis and atopic dermatitis.\u201d\n<\/p>\n

\nVTAMA\u00ae cream is a once-daily, topical medication for psoriasis. Currently, clinical trials are underway to study this medication among patients with atopic dermatitis.\n<\/p>\n

\n\u201cVTAMA\u00ae cream is a non-steroidal topical that is a new chemical entity and the first-in-class therapy to be approved in the topical psoriasis space in 25 years,\u201d says Anna Tallman, PharmaD, Vice-President of Medical Affairs at Dermavant Sciences. \u201cWe appreciate the collaboration and partnership with Dr. Bissonnette and Innovaderm to help bring forward an effective new treatment option in the United States that has the potential to benefit adults with plaque psoriasis across the entire disease severity spectrum \u2013 from mild to severe.\u201d\n<\/p>\n

\nDr. Bissonnette and Tallman recently contributed to an article on the phase 3 tapinarof studies, which was published in the New England Journal of Medicine. To learn more: https:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2103629<\/a>\n<\/p>\n

\nFor information on Innovaderm\u2019s early to late phase study capabilities, visit our website<\/a>.\n<\/p>\n

\nIMPORTANT SAFETY INFORMATION<\/b>\n<\/p>\n

\nIndication<\/b>: VTAMA\u00ae (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist approved in the US for the topical treatment of plaque psoriasis in adults. Adverse Events<\/b>: The most common adverse reactions (incidence \u2265 1%) in subjects treated with VTAMA cream were folliculitis (red raised bumps around the hair pores), nasopharyngitis (pain or swelling in the nose and throat), contact dermatitis (skin rash or irritation, including itching and redness, peeling, burning, or stinging), headache, pruritus (itching), and influenza (flu).\n<\/p>\n

\nYou are encouraged to report negative side effects of prescription drugs to the FDA. Visit http:\/\/www.fda.gov\/medwatch<\/a> or call 1-800-FDA-1088.\n<\/p>\n

\nSee full Prescribing Information and Patient Information<\/a>.\n<\/p>\n

\nInnovaderm Research Inc.<\/b>\n<\/p>\n

\nInnovaderm Research Inc. is a global, full-service CRO specialized in therapeutic dermatology. Founded in 2000, it partners with biotechnology and pharmaceutical companies for the collaborative management of early to late phase clinical trials. Its mission is to drive innovative research initiatives and offer new therapies for patients living with skin disease.\n<\/p>\n

\nDermavant Sciences<\/b>\n<\/p>\n

\nDermavant Sciences, a subsidiary of Roivant Sciences, is a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology. Dermavant\u2019s focus is to develop therapies that have the potential to address high unmet medical needs while driving greater efficiency in research and clinical development. The company\u2019s medical dermatology pipeline includes both approved and late-stage development product candidates the company believes may address important immuno-dermatological conditions, including plaque psoriasis and atopic dermatitis. For more information, please visit www.dermavant.com<\/a>, and follow us on Twitter (@dermavant<\/a>) and LinkedIn (Dermavant Sciences<\/a>).\n<\/p>\n

Contacts<\/b> <\/p>\n

\nFor more information:<\/b>
Kathy Giangaspero
\n
Communications Specialist
\n
Innovaderm Research Inc.
\n
kgiangaspero@innovaderm.com<\/a>\n<\/p>\n

\nAnna Tallman
\n
Vice-President, Medical Affairs
\n
Dermavant Sciences
\n
anna.tallman@dermavant.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

MONTREAL–(BUSINESS WIRE)–#DermatologyCRO–Innovaderm\u2019s involvement in all phases of the clinical development of tapinarof culminated with a tremendous achievement: the recent approval of Dermavant Sciences\u2019 VTAMA\u00ae (tapinarof) cream by the FDA for the treatment of plaque psoriasis in adults. Discovered in Canada, tapinarof is approved in the United States for the management of psoriasis, a chronic skin … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46444","6":"format-standard","7":"category-industry"},"yoast_head":"\nInnovaderm Shines as Key Partner in Clinical Development and Study Management of Newly FDA-Approved Psoriasis Drug, Tapinarof - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/innovaderm-shines-as-key-partner-in-clinical-development-and-study-management-of-newly-fda-approved-psoriasis-drug-tapinarof\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innovaderm Shines as Key Partner in Clinical Development and Study Management of Newly FDA-Approved Psoriasis Drug, Tapinarof - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MONTREAL–(BUSINESS WIRE)–#DermatologyCRO–Innovaderm\u2019s involvement in all phases of the clinical development of tapinarof culminated with a tremendous achievement: the recent approval of Dermavant Sciences\u2019 VTAMA\u00ae (tapinarof) cream by the FDA for the treatment of plaque psoriasis in adults. Discovered in Canada, tapinarof is approved in the United States for the management of psoriasis, a chronic skin ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/innovaderm-shines-as-key-partner-in-clinical-development-and-study-management-of-newly-fda-approved-psoriasis-drug-tapinarof\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-21T15:02:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220721005175\/en\/1519710\/21\/Logo_slogan-ENG.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innovaderm-shines-as-key-partner-in-clinical-development-and-study-management-of-newly-fda-approved-psoriasis-drug-tapinarof\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innovaderm-shines-as-key-partner-in-clinical-development-and-study-management-of-newly-fda-approved-psoriasis-drug-tapinarof\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Innovaderm Shines as Key Partner in Clinical Development and Study Management of Newly FDA-Approved Psoriasis Drug, Tapinarof\",\"datePublished\":\"2022-07-21T15:02:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innovaderm-shines-as-key-partner-in-clinical-development-and-study-management-of-newly-fda-approved-psoriasis-drug-tapinarof\\\/\"},\"wordCount\":619,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innovaderm-shines-as-key-partner-in-clinical-development-and-study-management-of-newly-fda-approved-psoriasis-drug-tapinarof\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220721005175\\\/en\\\/1519710\\\/21\\\/Logo_slogan-ENG.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innovaderm-shines-as-key-partner-in-clinical-development-and-study-management-of-newly-fda-approved-psoriasis-drug-tapinarof\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innovaderm-shines-as-key-partner-in-clinical-development-and-study-management-of-newly-fda-approved-psoriasis-drug-tapinarof\\\/\",\"name\":\"Innovaderm Shines as Key Partner in Clinical Development and Study Management of Newly FDA-Approved Psoriasis Drug, Tapinarof - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innovaderm-shines-as-key-partner-in-clinical-development-and-study-management-of-newly-fda-approved-psoriasis-drug-tapinarof\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innovaderm-shines-as-key-partner-in-clinical-development-and-study-management-of-newly-fda-approved-psoriasis-drug-tapinarof\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220721005175\\\/en\\\/1519710\\\/21\\\/Logo_slogan-ENG.jpg\",\"datePublished\":\"2022-07-21T15:02:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innovaderm-shines-as-key-partner-in-clinical-development-and-study-management-of-newly-fda-approved-psoriasis-drug-tapinarof\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innovaderm-shines-as-key-partner-in-clinical-development-and-study-management-of-newly-fda-approved-psoriasis-drug-tapinarof\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innovaderm-shines-as-key-partner-in-clinical-development-and-study-management-of-newly-fda-approved-psoriasis-drug-tapinarof\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220721005175\\\/en\\\/1519710\\\/21\\\/Logo_slogan-ENG.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220721005175\\\/en\\\/1519710\\\/21\\\/Logo_slogan-ENG.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/innovaderm-shines-as-key-partner-in-clinical-development-and-study-management-of-newly-fda-approved-psoriasis-drug-tapinarof\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innovaderm Shines as Key Partner in Clinical Development and Study Management of Newly FDA-Approved Psoriasis Drug, Tapinarof\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Innovaderm Shines as Key Partner in Clinical Development and Study Management of Newly FDA-Approved Psoriasis Drug, Tapinarof - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/innovaderm-shines-as-key-partner-in-clinical-development-and-study-management-of-newly-fda-approved-psoriasis-drug-tapinarof\/","og_locale":"en_US","og_type":"article","og_title":"Innovaderm Shines as Key Partner in Clinical Development and Study Management of Newly FDA-Approved Psoriasis Drug, Tapinarof - Pharma Trend","og_description":"MONTREAL–(BUSINESS WIRE)–#DermatologyCRO–Innovaderm\u2019s involvement in all phases of the clinical development of tapinarof culminated with a tremendous achievement: the recent approval of Dermavant Sciences\u2019 VTAMA\u00ae (tapinarof) cream by the FDA for the treatment of plaque psoriasis in adults. Discovered in Canada, tapinarof is approved in the United States for the management of psoriasis, a chronic skin ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/innovaderm-shines-as-key-partner-in-clinical-development-and-study-management-of-newly-fda-approved-psoriasis-drug-tapinarof\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-21T15:02:20+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220721005175\/en\/1519710\/21\/Logo_slogan-ENG.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/innovaderm-shines-as-key-partner-in-clinical-development-and-study-management-of-newly-fda-approved-psoriasis-drug-tapinarof\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/innovaderm-shines-as-key-partner-in-clinical-development-and-study-management-of-newly-fda-approved-psoriasis-drug-tapinarof\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Innovaderm Shines as Key Partner in Clinical Development and Study Management of Newly FDA-Approved Psoriasis Drug, Tapinarof","datePublished":"2022-07-21T15:02:20+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/innovaderm-shines-as-key-partner-in-clinical-development-and-study-management-of-newly-fda-approved-psoriasis-drug-tapinarof\/"},"wordCount":619,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/innovaderm-shines-as-key-partner-in-clinical-development-and-study-management-of-newly-fda-approved-psoriasis-drug-tapinarof\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220721005175\/en\/1519710\/21\/Logo_slogan-ENG.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/innovaderm-shines-as-key-partner-in-clinical-development-and-study-management-of-newly-fda-approved-psoriasis-drug-tapinarof\/","url":"https:\/\/pharma-trend.com\/en\/innovaderm-shines-as-key-partner-in-clinical-development-and-study-management-of-newly-fda-approved-psoriasis-drug-tapinarof\/","name":"Innovaderm Shines as Key Partner in Clinical Development and Study Management of Newly FDA-Approved Psoriasis Drug, Tapinarof - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/innovaderm-shines-as-key-partner-in-clinical-development-and-study-management-of-newly-fda-approved-psoriasis-drug-tapinarof\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/innovaderm-shines-as-key-partner-in-clinical-development-and-study-management-of-newly-fda-approved-psoriasis-drug-tapinarof\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220721005175\/en\/1519710\/21\/Logo_slogan-ENG.jpg","datePublished":"2022-07-21T15:02:20+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/innovaderm-shines-as-key-partner-in-clinical-development-and-study-management-of-newly-fda-approved-psoriasis-drug-tapinarof\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/innovaderm-shines-as-key-partner-in-clinical-development-and-study-management-of-newly-fda-approved-psoriasis-drug-tapinarof\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/innovaderm-shines-as-key-partner-in-clinical-development-and-study-management-of-newly-fda-approved-psoriasis-drug-tapinarof\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220721005175\/en\/1519710\/21\/Logo_slogan-ENG.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220721005175\/en\/1519710\/21\/Logo_slogan-ENG.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/innovaderm-shines-as-key-partner-in-clinical-development-and-study-management-of-newly-fda-approved-psoriasis-drug-tapinarof\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Innovaderm Shines as Key Partner in Clinical Development and Study Management of Newly FDA-Approved Psoriasis Drug, Tapinarof"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46444","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46444"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46444\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46444"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46444"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46444"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}